Impact Factor
4.14
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.27
1,449 total citations
h5-index
53
h5 depth signal
Cited share
82.8%
202 of 244
Total citations
1,449
Citation footprint
Metric signal
5.42
External metric anchor
Self-citation
4.5%
65 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
468
United States
445
Canada
140
Australia
118
Netherlands
102
Citing Fields of Research
Neurosciences
742
Psychiatry
717
Substance Abuse
518
Psychiatry & Psychology
109
Anesthetic & Pain Medicine
64
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,656
Articles tracked across the journal lifetime
Indexed publication set
244
202 cited publications
Last 12 months
194
16.2 publications/month
Open access share
46.9%
91 OA publications in the last year
Leading citing country
United Kingdom
468 citing publications
Leading citing field
Neurosciences
742 citing publications
Latest tracked publication
13 October 2026
10 recent records available
Coverage & Indexing History
v11n1, 1997-
v11n1, 1997-
Active Coverage
Research Focus & Classification
Indexed Subjects
Psychiatry
Neurosciences
Substance Abuse
Issuing & Sponsoring Bodies
Contributor
British Association for Psychopharmacology
Broad Categories
Psychopharmacology
Substance Abuse
Psychiatry
Neurosciences
MeSH Descriptors
Psychopharmacology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/02698811261488471
Open DOI
Adverse drug reactions associated with psychotropic medications combined with versus without lithium: A case/control pharmacovigilance analysis
Background: We assessed the association between different adverse drug reactions (ADRs) and patients with versus without lithium co-medication using data from the European drug surveillance program AMSP (German: “Arzneimittelsicherheit i...
02
DOI 10.1177/02698811261490221
Open DOI
Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis
Background: Psilocybin-assisted therapy (PAT) has emerged as a promising intervention for alcohol use disorder (AUD), yet contemporary clinical evidence has not been systematically synthesized to validate its clinical utility and safety ...
03
DOI 10.1177/02698811261478615
Open DOI
Effects of Δ 9 -tetrahydrocannabinol on affiliative social behaviour: A systematic review of rodent studies
Introduction: Affiliative social behaviour is critical for survival and well-being and is shaped by complex neurobiological systems, including the endocannabinoid system (ECS). Δ 9 -tetrahydrocannabinol (THC), the primary psychoactive co...
04
DOI 10.1177/02698811261488491
Open DOI
Proper assessment of the response to a test drug needs a treatment-free control group in the experimental design
In preclinical biomedical research, the response elicited by a test drug is commonly evaluated relative to the response produced by its vehicle, with the difference assumed to represent the magnitude of the drug’s action. However, there ...
05
DOI 10.1177/02698811261490197
Open DOI
Comment on “Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review”
06
DOI 10.1177/02698811261488486
Open DOI
Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes
Background: Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the...
07
DOI 10.1177/02698811261488466
Open DOI
Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review
Background: Many proteins integral to psychotropic agents’ pharmacokinetics (PK) and pharmacodynamics (PD) exhibit circadian variation in expression and function. Chronopharmacology examines the effect of circadian systems on the pharmac...
08
DOI 10.1177/02698811261488465
Open DOI
Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?
Clozapine is the most effective treatment for treatment-resistant schizophrenia, yet it is often introduced late. This article proposes a critical period hypothesis, arguing that clozapine is most effective when started during a stage of...
09
DOI 10.1177/02698811261481062
Open DOI
N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state
Background: Psychoactive serotonin 5-HT2A receptor agonists are potent modulators of awareness. Influential theories propose that psychedelics alter whole-brain dynamics by increasing neural signal diversity and dynamic flexibility. Beyo...
10
DOI 10.1177/02698811261473405
Open DOI
Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Background: The persisting effects questionnaire (PEQ) is a measure of self-reported positive and negative effects from psychedelic and other experiences. While this measure has been used in many studies on psychedelic substances, the sc...
Bibliographical & Catalog Notes
Description based on: Vol. 1, no. 3, published 1987; title from cover.
Also issued online.